Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms

Coeptis现在拥有SNAP-CAR NK和SNAP-CAR T细胞技术平台的专有权

WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ('Coeptis' or 'the Company'), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.

WEXFORD，Pa，2023年10月11日/PRNewswire/-Coeptis Therapeutics Holdings，Inc。（纳斯达克股票代码：COEP）（'Coeptis'或'该公司'），一家开发癌症创新细胞治疗平台的生物制药公司，今天宣布，它已扩大与匹兹堡大学的独家许可协议，将SNAP-CAR技术平台纳入自然杀伤（NK）细胞。

This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a 'universal' CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer..

该修订后的协议建立在与匹兹堡大学就SNAP-CAR T-Cell签订的原始独家许可协议的基础上，SNAP-CAR T-Cell是一种“通用”CAR T技术平台，旨在同时靶向多种抗原，并可能解决一系列血液学和实体瘤，包括HER2表达癌症。。

The addition of SNAP-CAR NK adds a third NK-focused technology to Coeptis' development portfolio. Recently Coeptis completed an exclusive license agreement with Deverra Therapeutics, which included rights to a proprietary allogeneic stem cell expansion and differentiation platform for the generation of NK cells from pooled donor cord blood CD34+ cells that are being used without HLA matching in first-in-human clinical trials.

SNAP-CAR NK的加入为Coeptis的开发组合增加了第三项以NK为重点的技术。最近，Coeptis完成了与Deverra Therapeutics的独家许可协议，其中包括专有同种异体干细胞扩增和分化平台的权利，用于从混合供体脐带血CD34+细胞产生NK细胞，这些细胞在人体内首次使用时没有HLA匹配临床试验。

This highly scalable and cost-effective cell generation platform combined with the universal SNAP-CAR technology has the potential to generate a first-in-class fully universal (no HLA matching and antigen agnostic) targeted cell therapy. Coeptis has also obtained exclusive rights from VyGen Bio to negotiate towards the acquisition of the GEAR™ cell therapy and companion diagnostic platforms, including CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma..

这种高度可扩展且具有成本效益的细胞生成平台与通用SNAP-CAR技术相结合，有可能产生一流的完全通用（无HLA匹配和抗原不可知）靶向细胞疗法。Coeptis还获得了VyGen Bio的独家权利，以便就收购该装备进行谈判™ 细胞疗法和伴随诊断平台，包括CD38-GEAR-NK，一种用于治疗CD38+癌症的自然杀伤（NK）细胞疗法，最初关注多发性骨髓瘤。。

'The original exclusive license agreement with the University of Pittsburgh was a watershed moment for Coeptis, and with the growing recognition of the potential of NK cells, we believe this amendment is another extremely important step for this partnership and for Coeptis,' said Dave Mehalick, President and CEO of Coeptis Therapeutics.

“与匹兹堡大学最初的独家许可协议是Coeptis的分水岭，随着人们越来越认识到NK细胞的潜力，我们相信这项修正案是这种合作和Coeptis的另一个极其重要的步骤，”Dave Mehalick，Coeptis Therapeutics总裁兼首席执行官。

'Expanding this agreement to include engineering of NK cells to generate SNAP-CAR NK therapies highlights our commitment to being on the leading edge of this important technology with a team that is fully capable of expanding upon the existing technology to incorporate and synergize with complementary technologies that we have brought inhouse to Coeptis, including assets recently in-licensed from Deverra Therapeutics.'.

“扩大这项协议，包括NK细胞工程以产生SNAP-CAR NK疗法，突出了我们致力于处于这项重要技术的前沿，团队完全有能力扩展现有技术，与互补技术相结合和协同我们为Coeptis带来的技术，包括最近从Deverra Therapeutics许可的资产。

'We are pleased to expand our partnership with Coeptis as we work to advance our efforts in developing a universal CAR-T system and believe NK cells have the potential to be an important cell type for developing better treatments for a range of cancers,' said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh.

“我们很高兴扩大与Coeptis的合作伙伴关系，因为我们努力推进开发通用CAR-T系统的努力，并相信NK细胞有可能成为开发更好的癌症治疗方法的重要细胞类型，”Jason Lohmueller博士，外科肿瘤学研究部外科和免疫学助理教授，匹兹堡大学。

'Expanding this agreement to include allogeneic NK cells enables our teams to develop cell therapies that can be developed with off-the-shelf convenience and greater access to patients. We continue to strive for therapies that can target multiple antigens simultaneously while also offering greater control over toxicity.'.

“扩大这一协议，包括同种异体NK细胞，使我们的团队能够开发细胞疗法，可以开发现成的便利性和更多的患者访问。我们继续争取能够同时靶向多种抗原的疗法，同时也提供对毒性的更好控制。

About Coeptis Therapeutics Holdings, Inc.

关于Coeptis Therapeutics Holdings，Inc。

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively 'Coeptis'), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

Coeptis Therapeutics Holdings，Inc.及其子公司，包括Coeptis Therapeutics，Inc。和Coeptis Pharmaceuticals，Inc。（统称为Coeptis'），是一家开发创新癌症细胞治疗平台的生物制药公司，有可能破坏传统治疗范式并改善患者预后。

Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

Coeptis的产品组合和权利由Deverra Therapeutics许可的资产突出显示，包括同种异体细胞免疫治疗平台和DVX201，临床阶段，未经修改的自然杀伤细胞治疗技术。此外，Coeptis正在开发一种通用的多抗原CAR T技术，该技术获得匹兹堡大学（SNAP-CAR）和装备的许可™ 细胞疗法和伴随诊断平台，Coeptis正在与VyGen Bio和Karolinska Institutet的领先医学研究人员合作开发。

Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer.

Coeptis的商业模式旨在通过许可协议，许可协议和共同开发关系最大化其当前产品组合和权利的价值，并签订战略合作伙伴关系以扩展其产品权利和产品，特别是针对癌症的产品权利和产品。

The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/..

该公司总部设在宾夕法尼亚州韦克斯福德，了解有关Coeptis访问的更多信息https://coeptistx.com/..

Cautionary Note Regarding Forward-Looking Statements This press release and statements of our management made in connection therewith contain or may contain 'forward-looking statements' (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended).

关于前瞻性陈述的警示 本新闻稿和我们与之相关的管理层声明包含或可能包含“前瞻性声明”（如1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条所定义，作为修订）。

Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as 'may,' 'will,' 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, we are making forward-looking statements.

前瞻性陈述包括关于我们的计划，目标，目标，策略，未来事件或表现以及基本假设的陈述，以及除历史事实陈述之外的其他陈述。当我们使用诸如“可能”，“将会”，“意图”，“应该”，“相信”，“期望”，“预期”，“项目”，“估计”或类似的表达方式时，我们正在做出前瞻性的陈述。

Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S.

前瞻性陈述不能保证未来的业绩，并且涉及重大风险和不确定性，可能导致实际结果与我们在前瞻性陈述中讨论的预期大不相同，甚至可能大不相同。可能导致这种差异的因素包括但不限于：（1）无法在纳斯达克资本市场维持本公司证券的上市；（2） Deverra许可资产整合将破坏公司当前计划和运营的风险；（3） 无法承认新许可资产的预期收益，这可能受到竞争，公司经济增长和管理增长以及雇用和留住关键员工的能力等因素的影响；（4） 公司正在开发的产品或新许可资产未通过临床试验或未经美国批准的风险。

Food and Drug Administration or other applicable regulatory authorit.

食品药品监督管理局或其他适用的监管机构。

CONTACTS

联络

Coeptis Therapeutics, Inc.Andy Galy, Sr. VP of Communications504-416-6965[email protected]

Coeptis Therapeutics，Inc。Andy Galy，Sr。通信副总裁504-416-6965[受电子邮件保护]

Tiberend Strategic Advisors, Inc.InvestorsDaniel Kontoh-Boateng862-213-1398[email protected]

Tiberend Strategic Advisors，Inc.InvestorsDaniel Kontoh-Boateng862-213-1398[电子邮件保护]

MediaDavid Schemelia609-468-9325[email protected]

MediaDavid Schemelia609-468-9325[电子邮件保护]

SOURCE Coeptis Therapeutics

来源Coeptis Therapeutics